pembrolizumab

targets

all catalysts(100)

News(10)

• Hype vs. reality: What pharma’s hottest R&D bets have actually proved
  New types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.
  biopharma_dive · 4h ago
• Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
  Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
  biospace · 12h ago
• As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
  AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…
  biospace · 1d ago
• Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
  At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xV…
  biospace · 1d ago
• Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
  Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors.
  stat · 4d ago
• After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
  A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.
  stat · 5d ago
• BioNTech mRNA cancer immunotherapy misses first objective in key study
  An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.
  biopharma_dive · 7d ago
• BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
  While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analyst…
  biospace · 7d ago
• STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more
  Patient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drug
  stat · 7d ago
• Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
  Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
  biospace · 7d ago